HRD	Fallopian Tube Cancer	HRD	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Peritoneal Cancer	HRD	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Peritoneal Cancer	HRD	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Fallopian Tube Cancer	HRD	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1
HRD + BRCA2 mutation	Ovarian Cancer	HRD + BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA1 mutation	Ovarian Cancer	HRD + BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2

HRD (Homologous Recombination Deficiency)

Associations(87)

Associations
(87)